Comparison Of Prognostic Factors In Patients With Lung Cancer Operated After Neoadjuvant Treatment
DOI:
https://doi.org/10.48729/pjctvs.534Keywords:
Neoadjuvant, non-small cell lung cancer, pulmonary resection, survivalAbstract
Aim: Lung cancer is the leading cause of cancer-related deaths worldwide. The most favorable treatment option for early-stage non-small cell lung cancer is surgical resection. In locally advanced lung cancer, surgery can be performed as part of multimodal treatment regimens. In this study, we aimed to investigate the survival outcomes and prognostic factors of non-small cell lung cancers operated on after neoadjuvant treatment.Methods: The data of patients who were operated on after neoadjuvant treatment in our clinic between 2012 and 2022 were collected. Data were analyzed according to age, gender, complete resection, applied treatment regimen, operation type, presence of viable tumor, histopathology, N status, tumor diameter, and presence of progression.
Results: A total of 96 patients were included in the study. There were 9 female (9.4%) and 87 male (90.6%) patients. The mean age was 65.2 ± 8.3. Median overall survival was 41 months (15.7-66.2), and 5-year overall survival was 42.4%. Poor prognostic factors for overall survival in our study are being older than 65 years (p=0.02), tumor progressing despite treatment (p=0.008), tumor diameter greater than 2.65 cm (p=0.01), incomplete resection (p=0.002), and tumor stage higher than stage I according to TNM classification 8th edition (p=0.02). There was no significant correlation between survival and gender, tumor histopathology, neoadjuvant treatment protocol, presence of viable tumor, presence of persistent N2, and type of surgery performed (p>0.05)
Conclusion: When planning surgery after neoadjuvant treatment in locally advanced lung cancer, there are some parameters to take into consideration which are age, tumor diameter after treatment, complete resectability, and the presence of diameter progression despite treatment.
Downloads
References
Global cancer observatory: Cancer today. Lyon: International Agency for Research on Cancer, 2020. Available at: https://goo.iacr.fr/today. Accessed April 15, 2023.
Nakamura K, Saji H, Nakajima R, Okada M, Asamura H et al. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Japanese journal of clinical oncology. 2010;40(3):271-4.
Jones CM, Brunelli A, Callister ME, Franks KN. Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the evidence? Curr Surg Rep. 2018;6:5.
Shinohara S, Takahashi Y, Masago K, Matsushita H, Kuroda H. The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review. J Thorac Dis. 2023;15(2):747-758. doi: 10.21037/jtd-22-957.
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T et al. Neoadjuvant Nirokumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med 2022; 386:1973-85.
Blumenthal GM, Bunn PA Jr, Chaft JE, McCouch CE, Perez EA et al. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018;13(12):1818-1831.
Albain KS, Rusch WW, Crowley JJ, Rice TW, Turrisi AT 3rd et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (NZ) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13:1880-92.
Karaman E, Ulas A, Onder AH, Deligonul A, Orhan SO, Pekcolaklar A. Role of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer in the COVID-19 Pandemic. Cureus. 2022 Sep 28;14(9): e29720.
Furrer K, Weder W, Eboulet EI, Betticher D, Pless M et al. Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. J Thorac Cardiovasc Surg. 2022;164(6):1587-1602 e5.
Zuin A, Marulli G, Breda C, Buff R, Schiavon M et al. Pneumonectomy for lung cancer over the age of 75 years: is it worthwhile? Interact Cardiovasc Thorac Surg. 2010 Jun;10(6):931-5; discussion 935.
Corsini EM, Weissferdt A, Patzer A, Zhou N, Antonoff MB et al. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Eur J Cardiothorac Surg. 2021 Jan 4;59(1):100-108.
Melek H, Geithkaya G, Özer E, Yentürk E, Seving TE et al. Pathological complete response after neoadjuvant/induction treatment: where is its place in the lung cancer staging system? Eur J Cardiothorac Surg. 2019 Sep 1;56(3):604-611.
Bettcher DC, Hsu Schmitz SF, Totsch M, Hansen E, Joss C et al; Swiss Group for Clinical Cancer Research (SAKX). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pNZ nonsmall- cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer. 2006 Apr 24;94(8):1099-106.
Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W et al. Non-Small Cell Lung Cancer, Version 3.2025, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. January 14, 2025.
Martin J, Ginsberg RJ, Abolhoda A, Bains MS, Downey RJ et al. Mobidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg. 2001 Oct;72(4):1149-54.
Hellmann MD, Chaft JE, William WN Jr, Rusch V, Fisters KM et al. University of Texas MD Anderson Lung Cancer Collaborative Group. Pathological response after neoadjuvant chemotherapy in resectable nonsmall- cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15(1): e42-50.
Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer: Morphology and prognosis. Chest 2001, 120, 1584-1591.
Friat S, Byhardt RW, Gore E. Comorbidity and Karnofsky performance score: an independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):357-64.
Zens P, Bello C, Scherz A, Koenigsdorf J, Pollinger A et al. A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response. Mod Pathol. 2021 Jul;34(7):1333-1344.
Akyil M, Tezel C, Tokgöz Akyil F, Güter D, Evman S et al. Prognostic significance of pathological complete response in non-small cell lung cancer following neoadjuvant treatment. Turk Gogus Kalp Damar Cerrahisi Deep. 2020;28(1):166-174.
Brunswicker A, Taylor M, Grant SW, Abah U, Smith M et al. North West Thoracic Surgery Collaborative (NWTSC). Pneumonectomy for primary lung cancer: contemporary outcomes, risk factors and model validation. Interact Cardiovasc Thorac Surg. 2022;34(6):1054-1061.
Broderick SR, Patel AP, Crabtree TD, Bell JM, Morganstern D et al. Pneumonectomy for Clinical Stage IIIA Non-Small Cell Lung Cancer: The Effect of Neoadjuvant Therapy. Ann Thorac Surg. 2016;101(2):451-7; discussion 457-8.
Collaud S, Bongioanni M, Pache JC, Fioretta G, Robert JH. Survival according to the site of bronchial microscopic residual disease after lung resection for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009 Mar;137(3):622-6.
Riquet M, Achour K, Foucault C, Le Pimpec Barthes F, Dujon A, Cases A. Microscopic residual disease after resection for lung cancer: a multifaceted but poor factor of prognosis. Ann Thorac Surg. 2010 Mar;89(3):870-5.
Downloads
Published
How to Cite
License
Copyright (c) 2025 Portuguese Journal of Cardiac Thoracic and Vascular Surgery
This work is licensed under a Creative Commons Attribution 4.0 International License.
